Assignee
CELGENE INT II SARL
CH·9 granted patents·8 pending applications·19 citations·filing 2014–2022
Top patents by PatentIndex Score
17 records- 0190US10018637B2Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilastCELGENE INT II SARL·Filed 2016·Granted Jul 10, 2018·7 cites·19 claims
- 0289US10259823B2GLP-1 receptor modulatorsCELGENE INT II SARL·Filed 2017·Granted Apr 16, 2019·7 cites·26 claims
- 0382US10793824B2Salt formulations for the fermentation of marine microorganismsCELGENE INT II SARL·Filed 2018·Granted Oct 6, 2020·1 cites·11 claims
- 0480US10239846B2Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisCELGENE INT II SARL·Filed 2017·Granted Mar 26, 2019·2 cites·10 claims
- 0578US2023210817A1Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2022·Application pending·0 cites
- 0676US10703760B2Morphic forms of marizomib and uses thereofCELGENE INT II SARL·Filed 2017·Granted Jul 7, 2020·1 cites·14 claims
- 0773US10034886B2GLP-1 receptor modulatorsCELGENE INT II SARL·Filed 2017·Granted Jul 31, 2018·1 cites·14 claims
- 0870US10610517B2Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2014·Granted Apr 7, 2020·0 cites·4 claims
- 0969US2021130768A1Salt formulations for the fermentation of marine microorganismsCELGENE INT II SARL·Filed 2020·Application pending·0 cites
- 1069US2023181534A1Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancersCELGENE INT II SARL·Filed 2022·Application pending·0 cites
- 1167US2020206190A1Compositions and methods for treating neoplastic diseasesCELGENE INT II SARL·Filed 2020·Application pending·0 cites
- 1265US11136332B2Morphic forms of marizomib and uses thereofCELGENE INT II SARL·Filed 2020·Granted Oct 5, 2021·0 cites·20 claims
- 1365US2022235063A1Morphic forms of marizomib and uses thereofCELGENE INT II SARL·Filed 2021·Application pending·0 cites
- 1460US11980606B2Use of marizomib for the treatment of central nervous system (CNS) cancersCELGENE INT II SARL·Filed 2020·Granted May 14, 2024·0 cites·8 claims
- 1549US2020085789A1Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancersCELGENE INT II SARL·Filed 2018·Application pending·0 cites
- 1649US2024246990A1Process of preparing (1r, 4r, 5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione(salinosporamide a; marizomib)CELGENE INT II SARL·Filed 2020·Application pending·0 cites
- 1739US2019345133A1Cxcr3 receptor agonistsCELGENE INT II SARL·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when CELGENE INT II SARL files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →